A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma

Trial Profile

A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs BNZ 1 (Primary)
  • Indications Cutaneous T cell lymphoma; Lymphoid leukaemia
  • Focus Adverse reactions
  • Sponsors Bioniz
  • Most Recent Events

    • 23 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 17 Jan 2018 Planned End Date changed from 30 Apr 2018 to 30 Dec 2018.
    • 17 Jan 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top